Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.62 |
| ▸ | GNAO1 | P09471 | 5/20 | 0.44 |
| ▸ | GNAI3 | P08754 | 4/20 | 0.44 |
| ▸ | GNAI1 | P63096 | 4/20 | 0.44 |
| ▸ | NAMPT | P43490 | 1/20 | 0.42 |
| ▸ | MAPT | P10636 | 1/20 | 0.38 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.38 |
| ▸ | ITGB3 | P05106 | 4/20 | 0.36 |
| ▸ | ITGA2B | P08514 | 4/20 | 0.36 |
| ▸ | KDM1A | O60341 | 1/20 | 0.35 |
| ▸ | MAOA | P21397 | 1/20 | 0.35 |
| ▸ | MAOB | P27338 | 1/20 | 0.35 |
| ▸ | EPHX1 | P07099 | 1/20 | 0.34 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1829059 | 0.94 | SIGMAR1 (0.53) | SIGMAR1GNAO1GNAI3GNAI1NAMPT | |
| SCHEMBL28485229 | 0.88 | SIGMAR1 (0.53) | SIGMAR1GNAO1GNAI3GNAI1NAMPT | |
| SCHEMBL2911869 | 0.85 | SIGMAR1 (0.42) | SIGMAR1GNAO1GNAI3GNAI1MAPT | |
| SCHEMBL6962219 | 0.84 | — | — | |
| SCHEMBL22519336 | 0.82 | SIGMAR1 (0.79) | SIGMAR1MAPTEPHX1 | |
| SCHEMBL21574012 | 0.82 | SIGMAR1 (0.79) | SIGMAR1MAPTEPHX1 | |
| SCHEMBL20207744 | 0.82 | SIGMAR1 (0.79) | SIGMAR1MAPTEPHX1 | |
| SCHEMBL331124 | 0.82 | HRH3 (0.47) | SIGMAR1GNAO1GNAI3GNAI1NAMPT | |
| SCHEMBL6969290 | 0.80 | SIGMAR1 (0.91) | SIGMAR1MAPTEPHX1 | |
| SCHEMBL18402615 | 0.80 | GNAO1 (0.54) | SIGMAR1GNAO1GNAI3GNAI1NAMPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3960726-A9 | AMINE CATIONIC LIPIDS AND USES THEREOF | Dicerna Pharmaceuticals, Inc. (US) | 2023-04-26 | — | — | EP | disclosed |
| WO-2023003862-A1 | CXCR4 MODULATORS AND USES RELATED THERETO | EMORY UNIVERSITY (US) | 2023-01-26 | — | — | WO | disclosed |
| US-11351265-B2 | Process for formulating an anionic agent | DICERNA PHARMACEUTICALS, INC. (US) | 2022-06-07 | — | — | US | disclosed |
| EP-3960726-A1 | AMINE CATIONIC LIPIDS AND USES THEREOF | Dicerna Pharmaceuticals, Inc. (US) | 2022-03-02 | — | — | EP | disclosed |
| EP-3597644-B1 | AMINE CATIONIC LIPIDS AND USES THEREOF | DICERNA PHARMACEUTICALS INC (US) | 2021-09-29 | — | — | EP | disclosed |
| US-20210292303-A1 | AMINE CATIONIC LIPIDS AND USES THEREOF | DICERNA PHARMACEUTICALS, INC. | 2021-09-23 | — | — | US | disclosed |
| US-11059807-B2 | Amine cationic lipids and uses thereof | DICERNA PHARMACEUTICALS, INC. (US) | 2021-07-13 | — | — | US | disclosed |
| EP-2768958-B1 | AMINE CATIONIC LIPIDS AND USES THEREOF | DICERNA PHARMACEUTICALS INC (US) | 2019-08-14 | — | — | EP | disclosed |
| US-20190151461-A1 | PROCESS FOR FORMULATING AN ANIONIC AGENT | DICERNA PHARMACEUTICALS, INC. (US) | 2019-05-23 | — | — | US | disclosed |
| US-20190084965-A1 | AMINE CATIONIC LIPIDS AND USES THEREOF | NOVO NORDISK A/S (DK) | 2019-03-21 | — | — | US | disclosed |
| US-20170137409-A1 | Amine Cationic Lipids and Uses Thereof | NOVO NORDISK A/S (DK) | 2017-05-18 | — | — | US | disclosed |
| US-9549983-B2 | Amine cationic lipids and uses thereof | DICERNA PHARMACEUTICALS, INC. (US) | 2017-01-24 | — | — | US | disclosed |
| US-20150374842-A1 | PROCESS FOR FORMULATING AN ANIONIC AGENT | NOVO NORDISK A/S (DK) | 2015-12-31 | — | — | US | disclosed |
| US-20140371293-A1 | Amine Cationic Lipids and Uses Thereof | DICERNA PHARMACEUTICALS, INC. (US) | 2014-12-18 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20190084965-A1 | AMINE CATIONIC LIPIDS AND USES THEREOF | SGMS2, SLC43A1, SGMS1 | SIGMAR1 666/4885GNAO1 2458/4885GNAI3 1574/4885 |
| US-11351265-B2 | Process for formulating an anionic agent | PHOSPHO1, POLRMT, LIPA | SIGMAR1 2747/4885GNAO1 1886/4885GNAI3 1891/4885 |
| US-20190151461-A1 | PROCESS FOR FORMULATING AN ANIONIC AGENT | PHOSPHO1, POLRMT, LIPA | SIGMAR1 2747/4885GNAO1 1886/4885GNAI3 1891/4885 |
| US-11059807-B2 | Amine cationic lipids and uses thereof | SGMS2, SLC43A1, SGMS1 | SIGMAR1 666/4885GNAO1 2458/4885GNAI3 1574/4885 |
| US-20150374842-A1 | PROCESS FOR FORMULATING AN ANIONIC AGENT | PHOSPHO1, POLRMT, LIPA | SIGMAR1 2747/4885GNAO1 1886/4885GNAI3 1891/4885 |
| US-20140371293-A1 | Amine Cationic Lipids and Uses Thereof | SGMS2, SLC43A1, SGMS1 | SIGMAR1 666/4885GNAO1 2458/4885GNAI3 1574/4885 |
| US-20170137409-A1 | Amine Cationic Lipids and Uses Thereof | SGMS2, SLC43A1, SGMS1 | SIGMAR1 666/4885GNAO1 2458/4885GNAI3 1574/4885 |
| US-20210292303-A1 | AMINE CATIONIC LIPIDS AND USES THEREOF | SGMS2, SLC43A1, SGMS1 | SIGMAR1 666/4885GNAO1 2458/4885GNAI3 1574/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.